Table 1.

Main characteristics of all studies included in the meta-analysis.

Author	Country	Year	Sample number	FIGO stage I/II/III/IV	Age	Follow-up months	Detected sample	Test way	Cut-off value (ng/mL)	Multivariate analysis	Survival analysis
Ouyang et al. [20]	China	2017	155	101/54/0/0	Median 47	Over 60	Serum	ELISA	1.5	Yes	OS
Jiang et al. [21]	China	2017	182	IB-IIA153/IIB-IIIB29	Mean 53	Over 60	Serum	ELISA	4	Yes	OS
Kim et al. [22]	Korea	2016	48	9/28/6/5	Median 52	Median 34	Serum	ELISA	2	Yes	PFS
Salvatici et al. [7]	Italy	2016	197	158/39/0/0	Median 43.9	Over 60	Serum	ELISA	1.5	Yes	OS, PFS
Ryu et al. [8]	Korea	2016	154	53/84/9/8	Median 59	Median 41	Serum	ELISA	1.86	Yes	DFS
Kotowicz et al. [6]	Poland	2016	138	38/40/57/3	Median 54	Over 60	Serum	ELISA	1.6/1.8	Yes	OS, DFS
Li et al. [9]	China	2015	286	IB1-IIA135/IIB-IIIB151	Median 45	Over 60	Serum	ELISA	3.5	No	OS, DFS
Binbin et al. [10]	China	2014	172	0/119/50/3	Median 49	Median 54.5	Serum	ELISA	3	Yes	OS, PFS
Shimura et al. [11]	Japan	2013	167	22/66/45/34	Median 58	Over 60	Serum	ELISA	2	No	DFS
Kawaguchi et al. [12]	Japan	2013	116	IIB33/IIIA6/IIIB64/IVA13	Median 68	Median 58.6	Serum	ELISA	1.15	No	OS, PFS
Hirakawa et al. [13]	Japan	2008	108	IB-2/II-57/III-46/IV-3	Median 50	Median 48	Serum	ELISA	1.5	Yes	DFS
Hsu et al. [14]	Taiwan	2007	38	IB-32/IIA-6	Median 50.8	Median 29.8	Serum	ELISA	NR	No	DFS
Qgino et al. [15]	Japan	2006	352	IIB-99/III-239/IVA-14	Median 61	Median 53	Serum	ELISA	6	Yes	DFS
Molina et al. [19]	Spain	2005	156	47/65/39/5	NR	Median 44	Serum	ELISA	2	No	OS, DFS
Huang et al. [16]	Taiwan	2012	188	22/125/37/4	Median 56.5	Median 58.2	Serum	ELISA	10	No	OS
Lee et al. [17]	Korea	2011	788	505/219/50/14	Median 51	Median 53.4	Serum	ELISA	1.6	Yes	OS, PFS
Ohno et al. [18]	Japan	2003	63	2/21/29/11	Median 66	Over 48	Serum	ELISA	1.5	Yes	OS, DFS

NR: no report; OS: overall survival; PFS: progression-free survival; DFS: disease-free survival.